Literature DB >> 16487412

Physician knowledge of Rome symptom criteria for irritable bowel syndrome is poor among non-gastroenterologists.

C Charapata1, H Mertz.   

Abstract

Rome I criteria are highly specific for irritable bowel syndrome (IBS) when red flag signs and symptoms are absent. Physician knowledge of Rome criteria may reduce diagnostic testing. We assessed: (i) physician knowledge of Rome criteria among internists, gastroenterologists and surgeons; (ii) laboratory and endoscopical testing suggested by physicians for sample IBS patients. Physicians of all training levels in internal medicine, gastroenterology, and surgery completed an anonymous questionnaire at a University Medical Center. Subjects were asked to identify Rome criteria among distracters. Sample IBS patients were presented, and physicians were asked to suggest a diagnostic workup based on the choices provided on the questionnaire. Rome knowledge was highest among gastroenterologists and lowest among surgeons. Physicians suggested endoscopical procedures in 67% of IBS patients with diarrhoea and in 46% with constipation. There was no difference among specialties in amount of laboratory or endoscopical testing suggested. Knowledge and use of the Rome criteria or their positive predictive value (PPV) for IBS did not correlate with reduced diagnostic testing. Education regarding the Rome criteria should be extended to surgical specialists who are likely to evaluate and operate on IBS patients. Endoscopical evaluation of IBS patients may be excessive.

Entities:  

Mesh:

Year:  2006        PMID: 16487412     DOI: 10.1111/j.1365-2982.2005.00750.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  8 in total

Review 1.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Translational Gap between Guidelines and Clinical Medicine: The Viewpoint of Italian General Practitioners in the Management of IBS.

Authors:  Massimo Bellini; Cesare Tosetti; Francesco Rettura; Riccardo Morganti; Christian Lambiase; Gabrio Bassotti; Pierfrancesco Visaggi; Andrea Pancetti; Edoardo Benedetto; Nicola de Bortoli; Paolo Usai-Satta; Rudi De Bastiani
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

3.  Celiac disease is uncommon in irritable bowel syndrome in the USA.

Authors:  Ann E Almazar; Nicholas J Talley; Joseph J Larson; Elizabeth J Atkinson; Joseph A Murray; Yuri A Saito
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-02       Impact factor: 2.566

4.  Irritable bowel syndrome: physicians' awareness and patients' experience.

Authors:  Linda Bjork Olafsdottir; Hallgrímur Gudjonsson; Heidur Hrund Jonsdottir; Jon Steinar Jonsson; Einar Bjornsson; Bjarni Thjodleifsson
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 5.  Study design considerations for irritable bowel syndrome clinical trials.

Authors:  Larry E Miller
Journal:  Ann Gastroenterol       Date:  2014

6.  Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Gregory S Sayuk; Ray Wolf; Lin Chang
Journal:  Am J Gastroenterol       Date:  2017-01-17       Impact factor: 10.864

7.  Creation of a Multispecialty Clinic for Patients with Central Sensitization-Based Chronic Pain Conditions.

Authors:  Conor G Loftus; Jon O Ebbert; Christopher A Aakre; Natalie A Caine; Meredith A DeZutter; Ryan J Eastman; Stephen M Fischer; Elizabeth A Gilman; Matthew G Johnson; Connie A Luedtke; Arya B Mohabbat; Karen J Reinschmidt; Daniel L Roellinger; William Sanchez; Lindsey M Philpot
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-12-23

8.  Exploring the agreement between diagnostic criteria for IBS in primary care in Greece.

Authors:  Foteini Anastasiou; Ioannis A Mouzas; Joanna Moschandreas; Elias Kouroumalis; Christos Lionis
Journal:  BMC Res Notes       Date:  2008-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.